Skip to main content
. 2010 May 23;2010:798467. doi: 10.1155/2010/798467

Figure 5.

Figure 5

Long-period administration of CTX improves survival compared to pre- or post-immunotherapy treatment. Mice were divided into four groups (n = 6 per group) and inoculated with a lethal dose of AB1 tumor cells on day 0. Mice received low-dose CTX before (day 3 till 10) or after (day 14 till 21) immunotherapy or metronomic dosed CTX (day 3 till 10 and day 14 till 21). Groups 2, 3, and 4 were treated with DC-immunotherapy on day 12. Group 1 functioned as a tumor control group and did not receive any treatment. Administration of metronomic dosed CTX was not significantly better than CTX treatment before (P = .840) or after (P = .454) immunotherapy. However, the combination of CTX and immunotherapy was significantly better than no treatment (CTX before immunotherapy compared to untreated P = .0081, CTX after immunotherapy compared to untreated P = .0147, metronomic dosed CTX and immunotherapy compared to untreated P = .0018).